SCHEMBL4385146

SCHEMBL4385146

O=C(O)CCC(=O)N1CCCC1c1cccnc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.54
BLM P54132 1/20 0.54
ALOX15 P16050 1/20 0.54
ALDH1A1 P00352 5/20 0.53
TDP1 Q9NUW8 3/20 0.53
MEN1 O00255 1/20 0.53
HPGD P15428 1/20 0.53
KMT2A Q03164 1/20 0.53
CHRNA7 P36544 2/20 0.52
CHRNB2 P17787 2/20 0.52
CHRNB4 P30926 2/20 0.52
CHRNA3 P32297 2/20 0.52
CHRNA4 P43681 2/20 0.52
CHRNA2 Q15822 2/20 0.52
LMNA P02545 2/20 0.52
HTR3E A5X5Y0 1/20 0.52
PSIP1 O75475 1/20 0.52
TRPA1 O75762 1/20 0.52
HTR3B O95264 1/20 0.52
CHRNA1 P02708 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4132486 0.85 ALDH1A1 (0.56) KDM4EBLMALOX15ALDH1A1TDP1
SCHEMBL19410088 0.85 ALDH1A1 (0.56) KDM4EBLMALOX15ALDH1A1TDP1
SCHEMBL28118098 0.85 ALDH1A1 (0.58) KDM4EBLMALOX15ALDH1A1TDP1
SCHEMBL30548844 0.84 ALDH1A1 (0.52) KDM4EBLMALOX15ALDH1A1TDP1
SCHEMBL18293369 0.84 ALDH1A1 (0.52) KDM4EBLMALOX15ALDH1A1TDP1
SCHEMBL30548843 0.84 ALDH1A1 (0.52) KDM4EBLMALOX15ALDH1A1TDP1
Nicotine SCHEMBL11351392 0.84 ALDH1A1 (0.77) KDM4EBLMALOX15ALDH1A1TDP1
(+/-)Nicotine SCHEMBL11351399 0.84 ALDH1A1 (0.77) KDM4EBLMALOX15ALDH1A1TDP1
(+/-)Nicotine SCHEMBL29482411 0.84 ALDH1A1 (0.77) KDM4EBLMALOX15ALDH1A1TDP1
SCHEMBL18293370 0.83 ALDH1A1 (0.51) KDM4EBLMALOX15ALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9994443-B2 Modified nicotinic compounds and related methods SELECTA BIOSCIENCES, INC. (US) 2018-06-12 US disclosed
US-9994443-B2 Modified nicotinic compounds and related methods SELECTA BIOSCIENCES, INC. (US) 2018-06-12 US disclosed
WO-2012061717-A1 MODIFIED NICOTINIC COMPOUNDS AND RELATED METHODS SELECTA BIOSCIENCES, INC. (US) 2012-05-10 WO disclosed
US-20120114677-A1 MODIFIED NICOTINIC COMPOUNDS AND RELATED METHODS SELECTA BIOSCIENCES, INC. (US) 2012-05-10 US disclosed
US-20120114677-A1 MODIFIED NICOTINIC COMPOUNDS AND RELATED METHODS SELECTA BIOSCIENCES, INC. (US) 2012-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120114677-A1 MODIFIED NICOTINIC COMPOUNDS AND RELATED METHODS NNMT, CHRNG, CHRM5 KDM4E 866/4885BLM 3442/4885ALOX15 2116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.